US EditionVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
- Virax Biolabs Group Limited received a notice from The Nasdaq Stock Market LLC about being non-compliant with the minimum bid price requirement.
- The minimum bid price requirement is $1.00 per share, and a deficiency exists if the price remains below this level for 30 consecutive business days.
- The company has until January 12, 2026, to regain compliance by maintaining a bid price of at least $1.00 for ten consecutive business days.
- The notification does not lead to immediate delisting, and shares will continue to trade under the symbol 'VRAX.
Insights by Ground AI
Does this summary seem wrong?
57 Articles
57 Articles
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The…
Coverage Details
Total News Sources57
Leaning Left8Leaning Right3Center14Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 32%
C 56%
12%
Factuality
To view factuality data please Upgrade to Premium
